2Seventy Bio Inc - Asset Resilience Ratio
2Seventy Bio Inc (TSVT) has an Asset Resilience Ratio of 16.25% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read TSVT total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2024)
This chart shows how 2Seventy Bio Inc's Asset Resilience Ratio has changed over time. See 2Seventy Bio Inc (TSVT) net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down 2Seventy Bio Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 2Seventy Bio Inc stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $78.02 Million | 16.25% |
| Total Liquid Assets | $78.02 Million | 16.25% |
Asset Resilience Insights
- Good Liquidity Position: 2Seventy Bio Inc maintains a healthy 16.25% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
2Seventy Bio Inc Industry Peers by Asset Resilience Ratio
Compare 2Seventy Bio Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.21% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 35.96% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.48% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 70.49% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
Annual Asset Resilience Ratio for 2Seventy Bio Inc (2020–2024)
The table below shows the annual Asset Resilience Ratio data for 2Seventy Bio Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 21.59% | $103.51 Million | $479.51 Million | -3.53pp |
| 2023-12-31 | 25.12% | $142.03 Million | $565.43 Million | -4.61pp |
| 2022-12-31 | 29.73% | $195.24 Million | $656.66 Million | +12.01pp |
| 2021-12-31 | 17.72% | $134.64 Million | $759.67 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $312.62 Million | -- |
About 2Seventy Bio Inc
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. 2seventy bio, Inc. was inco… Read more